Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15662835 | 1.00 | ALDH1A1 (0.34) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL346452 | 0.81 | POLB (0.34) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL2332494 | 0.76 | LMNA (0.32) | LMNA | |
| SCHEMBL345678 | 0.69 | POLB (0.35) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4009973 | 0.69 | SMN1; SMN2 (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL345746 | 0.64 | SCD5 (0.34) | RAB9ANPC1POLBHDAC6MEN1 | |
| SCHEMBL344838 | 0.63 | RAB9A (0.45) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL14069154 | 0.63 | THRB (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4009260 | 0.62 | RAB9A (0.44) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL17296417 | 0.62 | S1PR1 (0.41) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | ALDH1A1 2486/4885RAB9A 331/4885NPC1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.